Full-Time

Senior Medical Director

Drug Safety and Pharmacovigilance

BridgeBio

BridgeBio

501-1,000 employees

Develops therapies for genetic diseases

Compensation Overview

$325k - $370k/yr

+ Bonus + ESPP

United States

Hybrid

Remote but requires three in-person visits per year to the San Francisco office.

Category
Biology & Biotech (2)
,
Required Skills
Google Cloud Platform
Requirements
  • Medical Degree
  • Requires at least 12 years of drug safety and pharmacovigilance experience (clinical trials safety experience in the biotechnology, pharmaceutical, drug safety contract service organization (CSO)) with at least two years of oversight management experience (line management or CSO management)
  • Extensive experience with all aspects of safety signal evaluation, including review and analysis of data, collaboration with cross-functional team members and senior management, authoring of required regulatory correspondence, and safety label updates.
  • Experience in both clinical development and post-marketing safety
  • Experience with Regulatory submissions for NDAs, EU Marketing Authorisations Applications, and other countries’ Regulatory reviews
  • Demonstrated ability to successfully manage a drug safety team or drug safety CRO for a clinical development program with responsibilities for expedited reporting, on-time DSUR preparation
  • Experience in drug safety audits and agency inspections
  • Intimate knowledge of Good Clinical Practice and strong working knowledge of FDA, Good Clinical Practices, and ICH regulations and guidelines
  • Proven ability to collaborate successfully with clinical trial teams, including data management, clinical sciences, medical monitors, clinical operations, biostats, regulatory, medical writing, and QA
  • Experience in managing all clinical safety aspects of product quality defect investigations and assessments
  • Management of compliance deviations and formulation of corrective and preventive actions (CAPAs)
  • Familiar with clinical trial safety database use and CIOMS II and DSUR reporting generation (Argus, ArisG, or VeevaSafety) and Microsoft Office Suite required (Word, Excel, PowerPoint, Project, Outlook)
  • Must be able and willing to travel periodically for face-to-face engagements with regulatory authorities, and occasional on-site meetings (if based remotely)
  • Demonstrated curiosity and adaptability in adopting AI-powered tools and technologies
Responsibilities
  • Support the clinical development team in the review of key documents, including protocol and ICFs
  • Manage the drug safety contract service organizations (CROs) for clinical programs to ensure compliance with expedited reporting, manage on-time and scientifically sound DSUR preparation, and ensure the drug safety functions of the CROs meet corporate goals and key performance indicators
  • Assist in the medical review of adverse event reports; manage preparation and submission of drug safety expedited reporting in compliance with regulations, when necessary
  • Develop and prepare assessments of safety data, safety signals, and benefit/risk for internal senior management as well as external partner or regulatory authorities
  • Assist in the authoring of aggregate reports
Desired Qualifications
  • Demonstrated curiosity and adaptability in adopting AI-powered tools and technologies

BridgeBio Pharma develops medicines for genetic diseases through a decentralized subsidiary model, with each subsidiary focused on a specific disease while sharing central resources. It advances multiple drug programs at once by using genome sequencing, molecular biology, and patient data to identify targets and translate research into therapies. Therapies target the underlying genetic causes to create disease-modifying treatments, and BridgeBio monetizes via licensing, partnerships, and eventual commercialization of approved drugs. The company differentiates itself by its independent subsidiaries with centralized support, data-driven decision making, and a culture of radical transparency, all to accelerate discovery and bring therapies to patients faster.

Company Size

501-1,000

Company Stage

IPO

Headquarters

Palo Alto, California

Founded

2014

Simplify Jobs

Simplify's Take

What believers are saying

  • Attruby sales hit $146M in Q4 2025 with 44.7% mortality reduction.
  • BBP-418 meets Phase 3 endpoints in LGMD2I/R9 FORTIFY trial May 2026.
  • Farallon Capital boosts stake to 9M shares signaling pipeline confidence.

What critics are saying

  • Pfizer's Vyndamax erodes Attruby share via payer preference within 12 months.
  • $1.2B debt triggers breaches if Attruby growth drops below 30% YoY.
  • FDA rejects BBP-812 Canavan program halting 40% early pipeline value.

What makes BridgeBio unique

  • Hub-and-spoke model advances 48 disease programs via autonomous subsidiaries.
  • Focuses exclusively on genetic diseases and RAS/PI3Kα-driven cancers.
  • Partners with academics to rescue shelved early-stage genetic research.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Performance Bonus

Company Equity

Unlimited Paid Time Off

Growth & Insights and Company News

Headcount

6 month growth

-1%

1 year growth

0%

2 year growth

0%
Yahoo Finance
Mar 15th, 2026
BridgeBio Pharma shares drop 8% in a month despite 110% yearly gain and analyst target of $100

BridgeBio Pharma has fallen 8% over the past month and 7% over three months, despite posting a 110.52% one-year total shareholder return and approximately 4x returns over three years. The company closed at $69.41, with analysts from Vestra pointing to a fair value of $100.05, suggesting it's 30.6% undervalued. The valuation gap depends on BridgeBio's late-stage pipeline and its transition from research and development to commercial operations. However, the company continues to carry annual net losses of approximately $724.9 million, keeping financing and execution risks prominent. A separate DCF model estimates future cash flow value at $302.08, though this relies heavily on long-term assumptions around successful regulatory approvals and commercial uptake across its rare disease portfolio.

Yahoo Finance
Mar 7th, 2026
BridgeBio's BBP-418 hits Phase 3 endpoints in LGMD2I/R9, but $673M loss tests diversification thesis

BridgeBio Pharma announced positive interim Phase 3 FORTIFY trial data for BBP-418 in limb-girdle muscular dystrophy type 2I/R9, meeting efficacy endpoints. The company will present expanded results at the 2026 MDA Clinical and Scientific Conference alongside additional research. The successful readout represents a significant step for BBP-418 as a potential therapy for the rare genetic muscle disorder and could help diversify BridgeBio's revenue beyond its single approved drug, Attruby. However, the company remains unprofitable, reporting US$502 million in revenue against a US$725 million net loss in 2025. Analysts project BridgeBio could reach US$1.7 billion in revenue by 2028, with a fair value estimate of US$100.05 per share. The key risk remains high cash burn and potential dilution if expenses continue outpacing revenue growth.

Yahoo Finance
Mar 6th, 2026
Truist raises BridgeBio price target to $95 as Attruby sales hit $146M in Q4

BridgeBio Pharma has received upgraded price targets from analysts following strong fourth-quarter results. Truist raised its target to $95 from $86, maintaining a Buy rating, whilst Morgan Stanley increased its target to $98 from $96 with an Overweight rating. The company reported fourth-quarter revenue of $154.18 million, exceeding the $149.07 million consensus estimate. Pre-announced sales of its drug Attruby reached $146 million, a 35% increase from the third quarter, driven by accelerating new patient additions. CEO Neil Kumar highlighted the company's delivery of three successful Phase 3 trial readouts within three months. BridgeBio develops medicines for patients with genetic diseases and anticipates having six approved products as it completes its first decade.

Yahoo Finance
Jan 20th, 2026
Analysts raise BridgeBio price target to $86 after $362M Attruby revenue in 2025

BridgeBio Pharma has received positive analyst coverage following strong 2025 results. Truist raised its price target to $86 from $80 whilst maintaining a Buy rating, noting unchanged fundamental views from 2025. At the J.P. Morgan Healthcare Conference on 12 January, BridgeBio announced preliminary unaudited revenues of $146 million for the fourth quarter of 2025, bringing full-year product revenue to $362.4 million. The company reported over 6,000 unique prescriptions for Attruby, demonstrating rapid market adoption as a first-choice treatment for newly diagnosed ATTR-CM patients. BridgeBio develops therapies for genetic diseases and cancers, including its oncology-focused spin-off, BridgeBio Oncology Therapeutics, which advances precision cancer treatments targeting oncogenes like RAS and PI3K.

Stock Titan
Jan 16th, 2026
BridgeBio prices $550M convertible notes offering to prefund 2027 debt repayment

BridgeBio has priced an offering of $550 million in convertible senior notes due 2033. The biotech company plans to use the proceeds to prefund the repayment of its existing convertible senior notes due 2027. The refinancing move allows BridgeBio to extend its debt maturity profile by six years whilst managing its capital structure ahead of the 2027 notes coming due.